Medtech company Invamed has released their new clinical platform for beta enrollment as an AI-powered diagnostic application for imaging, lab, and genomic data.
Invamed’s Quantum offering was built on a large-scale multimodal transformer and trained on data points from global imaging archives, deidentified lab panels, genome sequences, and clinical literature, the company said in a statement.
Following the upload of imaging, lab, and genomic data onto the smartphone app, Quantum builds a biophysical simulation, i.e., a patient’s “digital twin,” according to Invamed. The platform will then offer recommendations for treatments, doses, and procedures, ranking them in order of efficacy and minimal adverse effects.
Quantum runs on iOS, Android, and modern browsers, Invamed added.
Invamed noted that it will be enrolling beta users through July 25, 2025. Developers and licensed clinicians who apply through Invamed’s website will gain access to REST/GraphQL APIs, synthetic MR and histology datasets, and a Docker-based AI-sandbox for custom module development.
